Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03629353 |
| Other study ID # |
THRIVE during LMS |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
August 17, 2018 |
| Est. completion date |
February 24, 2020 |
Study information
| Verified date |
September 2018 |
| Source |
Seoul National University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) was revealed to
prolong apneic time with a slow increase in carbon dioxide; thus, has been used for
preoxygenation in patients with difficult airways or requiring rapid sequence induction in
general anesthesia.
However, in patients undergoing hypopharyngeal and laryngo-tracheal surgery, THRIVE during
operation can be advantageous by allowing tubeless surgical field with sufficient
oxygenation.
Therefore, the investigators conducted this study to evaluate the efficacy of THRIVE on
prolonged apneic time with enhanced surgical conditions in patients with laryngeal
microsurgery.
Description:
Patients undergoing laryngeal microsurgery will be randomized into either intubation group or
THRIVE group.
On arriving operating room, the patients will be preoxygenated by facemask or high flow nasal
cannula with 100% oxygen for 3 minutes according to the allocated group. After inducing
general anesthesia, patients in intubation group will be oxygenated by endotracheal tube,
while patients in THRIVE group will be oxygenated by high flow nasal cannula with flow rate
of 70L/min. During the surgery, the endotracheal tube can be removed and reintubated in
intubation group patients to provide surgical field by a surgeon, respectively.
The monitored pulse oximetry, oxygen reserve index, and transcutaneous partial pressure of
carbon dioxide will be recorded during surgery.
